Yair Lotan, MD
Yair Lotan, M.D., is Professor of Urology, Chief of Urologic Oncology, and holder of the Helen J. and Robert S. Strauss Professorship in Urology at UT Southwestern Medical Center. He is also the Medical Director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System.
He was class valedictorian in high school and graduated with high honors from the University of Texas at Austin and Baylor College of Medicine in Houston. He trained in general surgery and urology at UT Southwestern and joined the faculty in 2003.
As a Professor of the Department of Urology at UT Southwestern, his practice focuses on oncology and endourology. His research is focused on the areas of bladder cancer screening, biomarkers, decision analysis, and health economics. He has participated in multiple collaborative studies involving early detection of bladder cancer. The goal is to improve diagnosis and management of bladder cancer as well as identify patients at risk for recurrence and progression. He is a co-investigator on several NIH funded trials evaluating urine-based tumor markers. He is the PI on several investigator-initiated studies evaluating the role of urine and tissue markers in the management of bladder cancer. He has also been involved in writing guidelines for the management of bladder cancer and chairing meetings focused on bladder cancer. He published over 450 peer-reviewed papers and multiple reviews and book chapters.
Dr. Lotan is the co-chair of the NCI designated Simmon’s Cancer Center disease oriented team for urologic cancers, UT Southwestern’s Clinical Research Planning Group, Tissue Bank Steering, and cancer committees. He is a frequent guest speaker at medical conferences around the world and belongs to numerous professional organizations, including the American Urological Association, Society of Urologic Oncology, and the Bladder Cancer Advocacy Network.
He also serves as editorial reviewer for medical periodicals such as the Journal of Urology, European Urology, Cancer, Urologic Oncology, and the British Journal of Urology International.